|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Informed by our previous work, we used a small EV carrying GPI-anchored PH20 hyaluronidase (Exo-PH20) that could deeply penetrate into tumour foci via HA degradation.
|
31632619 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
|
28949957 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Tumor cell-derived hyaluronidase HYAL-1 degrades hyaluronic acid (HA) into angiogenic fragments (AGF: 10-12 disaccharides).
|
27419371 |
2017 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
To minimize the premature release, hyaluronic acid (HA) was further coating on the outer surface of pSiO<sub>2</sub>, which would be degraded by over-expressed hyaluronidase (Hyal-1) in the tumor microenvironment.
|
28888002 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Tumor stage (P = .019) and HYAL-1 (P = .046) transcript levels were also associated with disease-specific mortality.
|
20960509 |
2011 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The tumor cell-derived hyaluronidase (HAase) HYAL-1 degrades hyaluronic acid (HA) into proangiogenic fragments that support tumor progression.
|
21555367 |
2011 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Importantly, a single intravenous dose of ICOVIR17 induced tumor regression in 60% of treated tumors.
|
20442708 |
2010 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Expression of Hyal 3 and Hyal 2 mRNA were >1000-fold and >30-fold greater respectively than that of Hyal 1 mRNA, the major Hyal expressed in other cancers.No Hyal type varied with tumor grade.
|
15936804 |
2005 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In ex vivo xenograft tumor cell lines, however, hyal-1 or hyal-2 mRNA levels were frequently elevated, whereas LUCA3 was only infrequently elevated and PH20 not at all.
|
11802201 |
2002 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Together, these results present new insights for HA degradation by Exo-PH20, providing a better understanding of oligo HA-triggered immune responses to cancer.
|
31632619 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although HYAL-1 is a critical determinant of tumor progression and a marker for cancer diagnosis and metastasis prediction, it has not been evaluated as a target for cancer therapy.
|
21555367 |
2011 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
PH-20 was abundant in all three extracts of all stages of cancer.
|
20849597 |
2010 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Expression of Hyal 3 and Hyal 2 mRNA were >1000-fold and >30-fold greater respectively than that of Hyal 1 mRNA, the major Hyal expressed in other cancers.No Hyal type varied with tumor grade.
|
15936804 |
2005 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Stratification of specimen by race revealed that African American women had higher levels of PH-20 with invasive and metastatic beast cancer.
|
11922735 |
2002 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We have investigated whether cell lines derived from such malignancies expressed Hyal-1 activity, using normal human keratinocytes as controls.
|
10702795 |
2000 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Together, these results present new insights for HA degradation by Exo-PH20, providing a better understanding of oligo HA-triggered immune responses to cancer.
|
31632619 |
2019 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Urine and tissue HAase/HYAL-1 levels are sensitive markers for high-grade bladder cancer (BCa) and its metastasis.
|
27419371 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Although HYAL-1 is a critical determinant of tumor progression and a marker for cancer diagnosis and metastasis prediction, it has not been evaluated as a target for cancer therapy.
|
21555367 |
2011 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
In univariate and multivariate analyses, tumor stage (P = .003), lymph node invasion (P = .033), HYAL-1 (P = .019), and HAS1 (P = .027) transcript levels, and HYAL-1 staining (P = .021) were independently associated with metastasis.
|
20960509 |
2011 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Although HYAL-1 is a critical determinant of tumor progression and a marker for cancer diagnosis and metastasis prediction, it has not been evaluated as a target for cancer therapy.
|
21555367 |
2011 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
PH-20 was abundant in all three extracts of all stages of cancer.
|
20849597 |
2010 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
PH-20 was present in 12/12 (100%) normal breast tissues; 8/12 (66.7%) DCIS; 13/13 (100%) invasive breast cancers; and 8/14 (57.1%) metastases.
|
11922735 |
2002 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Stratification of specimen by race revealed that African American women had higher levels of PH-20 with invasive and metastatic beast cancer.
|
11922735 |
2002 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
At IC50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P<0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ-Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity.
|
27419371 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In univariate and multivariate analyses, tumor stage (P = .003), lymph node invasion (P = .033), HYAL-1 (P = .019), and HAS1 (P = .027) transcript levels, and HYAL-1 staining (P = .021) were independently associated with metastasis.
|
20960509 |
2011 |